Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Ann Epidemiol. 2018 Jun 22;28(12):833–840. doi: 10.1016/j.annepidem.2018.06.009

Table 5.

Sensitivity analysis of estimated PrEP users in 2017, by reasonable estimates of missing pharmacy data and classification of TDF/FTC monotherapy as PrEP.

Year 2017 Percent of Truvada prescriptions not captured by SHA*
0% 10% 20% 25% 30%
Percent of
unclassified
Truvada
monotherapy used
for PrEP† 		0% 100,282 111424 125353 133709 143260
25% 111116 123462 138895 148154 158737
50% 121950 135499 152437 162599 174214
75% 132783 147537 165979 177044 189690
87% 137983 153315 172479 183978 197119
100% 143617 159574 179521 191489 205167
*

SHA estimates that 20% of all prescriptions are not included in their database.

†

In a previous analysis (data not shown) of Truvada monotherapy, 87% was for PrEP, 4% for management of chronic Hepatitis B infection, and 9% for HIV post-exposure prophylaxis.